3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
6
Esophageal Neoplasms
4
Gastrointestinal Neoplasms
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Adenocarcinoma
2
Solid Tumor
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Neoplasms, Unknown Primary
1
Nasopharyngeal Carcinoma
1
Locally Advanced Gastric Adenocarcinoma
1
Hand-Foot Syndrome
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Gemcitabine
9
Carboplatin
8
Paclitaxel
7
Capecitabine
7
Irinotecan
6
pembrolizumab
3
Radiotherapy
3
Oxaliplatin
3
Fluorouracil
3
Filgrastim
3
Cisplatin
3
Bevacizumab
3
etoposide phosphate
2
Surveys and Questionnaires
2
Peripheral Blood Stem Cell Transplantation
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Genetic Testing
2
FAPI-46
2
Etoposide
2
Erlotinib Hydrochloride
2
Docetaxel
2
Cyclophosphamide
2
Amifostine
2
Albumin-Bound Paclitaxel
2
tislelizumab
1
tegafur-gimeracil-oteracil
1
spartalizumab
1
sintilimab
1
erythromycin propionate-N-acetylcysteinate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms, Unknown Primary
×
tegafur-gimeracil-oteracil
×
Clear all
NCT01845337
2023-05-12
TOFFEE
University of Edinburgh
Phase 2
Completed
59 enrolled